In addition to its role in mucosal immunity and viral infections, IFN-λ has been recently proposed as the treatment of choice for IAV infection because its antiviral activity was not associated with an exacerbation of inflammation in contrast to IFN-α (32). The gene discussed is IFNA1; the disease is viral infectious disease.